News | October 21, 2023
Aarti Drugs Q2 FY24 consolidated net profit drops QOQ to Rs. 39.59 Cr
Aarti Drugs has reported total income of Rs. 642.22 crores during the period ended September 30, 2023
Aarti Drugs has reported total income of Rs. 642.22 crores during the period ended September 30, 2023
Three block copolymers added to RESOMER portfolio of bioabsorbable polymers
Glenmark's Zita portfolio of medicines have been benefiting around 1.75 million Type 2 diabetic patients annually
Venus Remedies' oncology wing has also secured marketing authorisation from Myanmar for another chemotherapy drug
The NDA filing for deuruxolitinib with the U.S. FDA is based on two pivotal Phase III trials
NRT offers 50% higher success rate in quitting smoking compared to unassisted attempts
The extension builds upon an existing long-term collaboration for end-to-end ADC manufacturing, including payload, monoclonal antibody (mAb) manufacturing and bioconjugation
The VitalDose Drug Delivery Platform has been used in patient-centric dose forms in women’s health for over two decades
In 2030 over 50% of FDA approvals will involve AI discovered and developed drugs
This collaboration marks a significant milestone in countering the disease burden by enhancing access to products for patients in the US
Subscribe To Our Newsletter & Stay Updated
